文献速递慢阻肺

基线症状评分对格隆溴铵/福莫特罗计量吸入器在COPD中获益的影响

Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.
PubMed 文献 · Chest · 2017-07-16

基于两项III期试验(NCT01854645和NCT01854658)的事后汇总分析,纳入3,699例COPD患者,评估基线CAT评分是否影响GFF MDI(18/9.6 μg)的疗效。结果显示,无论基线CAT评分如何,GFF MDI对FEV1的改善幅度相似;但健康状态、急救药物使用和急性加重风险的获益随基线CAT评分升高而增大。提示双支气管扩张剂对有症状患者的临床获益更大。

要点

  • GFF MDI对FEV1的改善不随基线CAT评分变化。
  • 基线CAT评分越高,GFF MDI对健康状态和急救药物使用的改善越明显。
  • 有症状的COPD患者从双支气管扩张剂中临床获益更大。

核心结论

  • GFF MDI对健康状态、急救药物使用和急性加重风险的获益随基线症状负担增加而增大,而肺功能获益与基线症状负担无关。

研究设计与样本

  • 两项24周III期试验(NCT01854645和NCT01854658)的事后汇总分析,纳入3,699例中重度至极重度气流受限且症状范围广泛的COPD患者。

主要发现

  • 第24周时,GFF MDI与单组分MDI及安慰剂MDI相比,FEV1改善幅度在各基线CAT评分组间相似。
  • GFF MDI与单组分MDI及安慰剂MDI相比,圣乔治呼吸问卷总分平均差异的幅度随基线CAT评分升高而增大。
  • GFF MDI组中,急救药物使用减少和急性加重风险降低在高基线症状负担患者中更明显。

临床怎么用

  • 对于症状负担较高的COPD患者,可优先考虑使用GFF MDI等双支气管扩张剂以获取更大的临床获益。

局限性

  • 为事后分析,证据等级受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that demonstrated better improvement of lung function with glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) (an MDI fixed-dose of GFF 18/9.6 μg) over individual monocomponent MDIs included a cross-section of patients with moderate to very severe airflow limitation and a broad range of COPD symptoms. METHODS: These post hoc analyses of pooled data investigated whether baseline symptom burden, assessed using the COPD Assessment Test (CAT) score, impacted GFF MDI-associated improvements in lung function, health status, rescue medication use, and exacerbation risk. RESULTS: In 3,699 patients, improvement in FEV1 at week 24 between the GFF MDI and monocomponent MDIs and a placebo MDI was similar in magnitude regardless of baseline CAT score. In contrast, the magnitude of mean difference in the St. George's Respiratory Questionnaire total score for GFF MDI vs monocomponent MDIs and the placebo MDI increased with increasing baseline CAT scores. Likewise, reduced rescue medication use and lower exacerbation risk were more pronounced in GFF MDI groups with a higher baseline symptom burden. CONCLUSIONS: Beneficial effects of GFF MDI on health status, rescue medication use, and exacerbation risk in symptomatic patients with COPD increased as a function of baseline symptom burden, whereas lung function benefits were independent. These data suggest a greater clinical benefit from dual bronchodilators in symptomatic patients than in patients without symptoms. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01854645 and NCT01854658; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Martinez FJ, Fabbri LM, Ferguson GT, et al. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. Chest. 2017. PMID: 28720336. doi:10.1016/j.chest.2017.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。